77377-27-6

Basic information

• Product Name: 3-QUINOLIN-8-YLACRYLIC ACID
• Synonyms: 3-QUINOLIN-8-YLACRYLIC ACID;2-Propenoic acid,3-(8-quinolinyl)-
• CAS NO: 77377-27-6
• Molecular Formula: C₁₂H₉NO₂
• Molecular Weight: 199.21
• Mol File: 77377-27-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 408.022°C at 760 mmHg
• Flash Point: 200.565°C
• Appearance: /
• Density: 1.307g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.712
• CAS DataBase Reference: 3-QUINOLIN-8-YLACRYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-QUINOLIN-8-YLACRYLIC ACID(77377-27-6)
• EPA Substance Registry System: 3-QUINOLIN-8-YLACRYLIC ACID(77377-27-6)

Safety Data

• Hazardous Substances Data: 77377-27-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H9NO2/c14-11(15)7-6-10-4-1-3-9-5-2-8-13-12(9)10/h1-8H,(H,14,15)/b7-6+

Upstream product

• 38707-70-9 8-formylquinoline 
• 141-82-2 malonic acid 

Relevant articles and documents

-

-

CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS

This invention pertains to certain carbamic acid compounds of the following formula, which inhibit HDAC (histone deacetylase) activity wherein: A is independently an unsubstituted or substituted bicyclic C9-10heteroaryl group (e.g., quinolinyl; quinoxalinyl; benzoxazolyl; benzothiazolyl); Q is an acid leader group, and is independently an unsubstituted or substituted, saturated or unsaturated C1 7alkylene group having a backbone length of 4 or less; with the proviso that if A is unsubstituted benzothiazol-2-yl, then Q is an unsaturated group; and with the proviso that if A is unsubstituted quinolin-6-yl, then Q is unsubstituted at the α-position; and with the proviso that A is not benzimidazol-2-yl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both invitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.